How This Works
Semaglutide is a GLP-1 receptor agonist with 94% sequence homology to native human GLP-1. It promotes weight loss through multiple mechanisms: reducing appetite and food intake via central nervous system effects, slowing gastric emptying, and improving glycemic control through glucose-dependent insulin secretion. The extended half-life of approximately 7 days is due to albumin binding and resistance to DPP-4 degradation, enabling convenient once-weekly dosing.
Clinical trials have demonstrated significant weight loss (mean 10–15% body weight reduction) in individuals with obesity when combined with lifestyle interventions. The weekly 2.4 mg maintenance dose is FDA-approved for chronic weight management and represents the standard clinical approach.
Potential Benefits & Side Effects
Observations from clinical literature and regulatory approvals.
Potential Benefits:
Significant weight loss (mean 10–15% body weight reduction in clinical trials at 2.4 mg weekly dose) when combined with lifestyle modifications.
Improved glycemic control through enhanced glucose-dependent insulin secretion and reduced glucagon secretion.
Reduced appetite and food intake via central nervous system GLP-1 receptor activation.
Cardiovascular benefits demonstrated in outcome trials, including reduced risk of major adverse cardiovascular events.
Convenient once-weekly dosing improves adherence compared to daily regimens.
Potential Side Effects:
Gastrointestinal effects (most common): nausea, vomiting, diarrhea, constipation, abdominal pain—typically mild to moderate and decreasing with gradual dose escalation.
Injection-site reactions: redness, swelling, or irritation (generally mild and transient).
Hypoglycemia risk (when combined with insulin or sulfonylureas)—less common with semaglutide monotherapy due to glucose-dependent mechanism.
Rare serious adverse events: pancreatitis, gallbladder disease, acute kidney injury; thyroid C-cell tumors observed in rodent studies (relevance to humans uncertain).
Dosage Guide: http://help.datapeptides.com/en/articles/15074325-semaglutide-5mg-vial-dosage-protocol
Disclaimer:
The information provided in this article is for educational and informational purposes only and is not intended as medical advice. These statements have not been evaluated by the FDA or Health Canada. Peptides and other compounds discussed are intended for research purposes only and are not approved for human consumption unless prescribed by a licensed medical professional. Always consult your healthcare provider before starting any new protocol, supplement, or treatment.